Global Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market Size & Trends Report Segmented by Drug Type (Alpha-Blockers, 5-Alpha Reductase Inhibitors), Procedure Type (TURP, Laser), Therapy (Mono, Combination), End-user (Hospitals, ASCs) & Regional Forecast to 2031

Benign Prostatic Hyperplasia (BPH) Surgical Treatment includes procedures that help relieve urinary problems caused by an enlarged prostate. When medicines no longer work well or symptoms become difficult to manage, doctors use surgical or minimally invasive methods to remove or open the blocked prostate tissue so urine can flow more easily. Common options include TURP, laser-based procedures, UroLift, Rezūm, Aquablation, and prostatic artery embolization among others. Each method differs in how it is done, the recovery time, and how long the results last. The choice of treatment usually depends on prostate size, the patient’s health, and the severity of symptoms.

Increasing ageing male population & growing BPH prevalence is driving the market growth

An ageing male population is one of the clearest reasons the BPH surgical treatment market keeps growing. BPH becomes more common as men get older, and most men eventually experience some degree of prostate enlargement. In 2021, there were 112,502 thousand prevalent cases globally, compared to 50,705.8 thousand cases in 1990, representing a 122% increase (Source: NCBI). By age 60, half of all men will have BPH and by age 85, the proportion most likely reaches 90% (Source: Harvard Health Publishing). As the number of men over 50 continues to rise in almost every region, the number of people dealing with noticeable urinary symptoms also increases. This naturally leads to more patients who reach the point where medicines no longer help enough and a procedure becomes the next option. Health systems are seeing larger volumes of men needing care, and this affects the types of treatment that gain traction. Older patients often have other medical conditions, may be on blood thinners, and may not tolerate long or invasive surgeries well. Because of this, hospitals and clinics increasingly look for procedures that are safer, quicker, and easier to perform outside of traditional operating rooms. This shift supports the use of minimally invasive options such as UroLift, Rezūm, laser procedures, Aquablation, and prostatic artery embolization.

As more men develop symptoms, screening and diagnosis also increase. This means more individuals enter the treatment pathway earlier, creating a steady stream of patients who may eventually choose surgery or a minimally invasive procedure. Providers are expanding outpatient and ambulatory surgery center capacity to handle these volumes in a cost-effective way. Manufacturers see this demographic trend as stable and long-term, which encourages them to invest in new devices, training programs, and evidence to support adoption. Even markets that are younger today are ageing quickly, so the demand is not limited to a few countries.

In basic terms, more older men mean more BPH, and more BPH means a consistent need for procedures that relieve symptoms. This steady rise in eligible patients, combined with the shift toward less invasive care, is a major factor pushing the BPH surgical treatment market forward.

To learn more about this report, download the PDF brochure

Shift toward minimally invasive surgical therapies (MISTs) to propel market demand

The move toward minimally invasive surgical therapies (MISTs) is becoming a major reason the BPH treatment market is growing. Older surgical options like TURP are still used, but they come with longer hospital stays, more discomfort, and a recovery period that many patients want to avoid. As newer procedures have shown good results with fewer complications, more patients and doctors are choosing them. This change in preference is gradually shaping how BPH is treated today. Treatments such as UroLift, Rezūm, and laser-based methods usually take less time and do not involve as much tissue removal. They also tend to have lower risks of bleeding or sexual side effects. Because of this, most patients can get back to their normal routine sooner. For healthcare providers, these procedures can be done in outpatient settings or ambulatory surgery centers, which reduces hospital workloads and operating room demand. These practical benefits are encouraging doctors to use MISTs more often.

Patient expectations also play a big part. Many men, including those who are still working or managing other health issues, prefer procedures that do not disrupt daily life for long. Since several MISTs can be done with local anesthesia, they are suitable for older adults or people who may not tolerate traditional surgery well.

Growing clinical data is also helping adoption. Studies now show that these procedures offer lasting relief, a low rate of complications, and fewer repeat treatments. As this information becomes more familiar to clinicians, they are more comfortable recommending MISTs earlier in the treatment process. Insurance coverage and wider availability of trained specialists are adding momentum. As more providers learn these techniques and reimbursement improves, access increases across different care settings. Altogether, these factors are steadily pushing the market toward minimally invasive options and making MISTs a core part of BPH management.

Recent developments in the BPH surgical treatment market

Players operating in this market are adopting different growth strategies such as new product launches, investments, approvals, and expansions to garner market share. For instance,

• In August 2025, ProVerum raised USD 80 million in Series B funding to advance its ProVee System, a minimally invasive nitinol-based solution for treating BPH. The investment, led by MVM Partners with major global investors, will support clinical progress and future commercialization of the device
• In February 2025, Olympus expanded the availability of its minimally invasive iTind device for BPH treatment across six Asia-Pacific markets, including an upcoming launch in Korea. The company is also rolling out physician training programs to support adoption and strengthen BPH care in the region
• In July 2023, Urotronic received FDA approval for its Optilume BPH Catheter System, a minimally invasive treatment that combines balloon dilation with localized paclitaxel delivery for BPH-related urinary symptoms. Backed by strong multi-year clinical data, the device offers a no-cut, no-implant outpatient option positioned as a next-generation solution in BPH therapy

To learn more about this report, download the PDF brochure

Drug Type Segment Outlook

Alpha-blockers make up the largest share of the BPH drug market as they are usually the first medicines doctors prescribe. They work quickly, are easy to tolerate, and are used for a broad range of patients, which keeps their overall use high. On the other hand, 5-alpha reductase inhibitors are growing the fastest. These drugs help shrink the prostate, slow disease progression, and reduce the chance of future complications, which is increasing their adoption. Their role in combination therapy and the rising number of patients with moderate to severe BPH are also driving this faster growth.

Regional Outlook: North America expected to hold a major share in the BPH surgical treatment market

North America is the largest market for BPH surgical treatments owing to the strong healthcare systems and good insurance coverage, coupled with a large aging male population that drives steady demand. APAC is the fastest-growing region, mainly due to its rapidly aging demographics, improving healthcare access, and rising use of minimally invasive procedures in countries like China, India, Japan, and South Korea. Europe remains an important and well-established market, while Latin America and the Middle East & Africa are smaller but gradually expanding as healthcare infrastructure, device availability, and reimbursement systems continue to improve.

Competitive Landscape Analysis

The global BPH surgical treatment market is marked by the presence of established and emerging market players such as Eli Lilly and Company (US); GSK plc. (UK); Boston Scientific Corporation (US); Teleflex Incorporated (US); PROCEPT BioRobotics Corporation (US); Olympus Corporation (Japan); Astellas Pharma Inc. (Japan); Asahi Kasei Corporation (Japan); Coloplast Group (Denmark); and AbbVie Inc (US); among others. Some of the key strategies adopted by market players include product innovation and development, strategic partnerships and collaborations, mergers and acquisitions, and geographic expansion.

Get a sample report for competitive landscape analysis

Report Scope

Global BPH surgical treatment Market Segmentation

This report by Medi-Tech Insights provides the size of the global BPH surgical treatment market at the regional- and country-level from 2024 to 2031. The report further segments the market based on drug type, procedure type, therapy, and end user.

Market Size & Forecast (2024-2031), By Drug Type, USD Billion

• Alpha-Blockers
• 5-Alpha Reductase Inhibitors
• Other Drug Types

Market Size & Forecast (2024-2031), By Procedure Type, USD Billion

• Transurethral Resection of the Prostate (TURP)
• Laser Surgeries
• UroLift Procedures
• Rezum Procedures
• Robot-Assisted Waterjet Ablation
• Prostatic Stents
• Transurethral Microwave Thermotherapy (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Prostatic Arterial Embolization (PAE)
• Other Procedure Types

Market Size & Forecast (2024-2031), By Therapy, USD Billion

• Mono Therapy
• Combination Therapy

Market Size & Forecast (2024-2031), By End-user, USD Billion

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports: 

Global Prostate Cancer Diagnostics Market Size & Trends Report Segmented by Type (Adenocarcinoma, Interstitial Cell Carcinoma), Test Type (Preliminary, Confirmatory), End-user (Hospitals, Outpatient Clinics, Home-care Settings) & Regional Forecast to 2030

Global Transrectal Ultrasound Market Size & Trends Report Segmented by Product Type (Cart / Trolley-based), Application (Diagnostic, Image-guided Biopsy), Technology (2D, 3D, 4D), End-user (Hospitals, Diagnostic Imaging Centers, Specialty Clinics) & Regional Forecast to 2030

Global Urology Imaging Systems Market Size & Trends Report Segmented by Product (Ultrasound, X-Ray, CT, Others), Application (Diagnostic, Interventional), End-user (Hospitals, Diagnostic Imaging Centers, Others) & Regional Forecast to 2030